Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
Charles D HowellVirahep-C Study Group

Abstract

The relationship between serum peginterferon pharmacokinetics and pharmacodynamics and the early virologic response (EVR) to peginterferon and ribavirin therapy was assessed in patients with chronic hepatitis C virus (HCV) genotype 1 infection. A total of 333 patients (160 African Americans [AA] and 173 Caucasian Americans [CA]) who received peginterferon alpha-2a (180 microg/wk) without a dose modification during the initial 4 weeks of therapy were analyzed. Peginterferon and 2,5-oligoadenylate synthetase (2,5-OAS) serum levels were measured on days 0, 1, 2, 3, 7, 14, 28, 56, 84, and 168 of treatment. The EVR (>or=2-log(10) decline in HCV RNA levels by week 12 of therapy) was the primary virologic end point. Peginterferon pharmacokinetics after the first dose were similar in AA and CA, but AA had greater peginterferon concentrations at days 1, 3, 14, and 28 (P < .05). AA had higher absolute serum 2,5-OAS levels on days 0, 1, 2, 3, 7, 14, 28, and 56 (P < .05), but the magnitude of 2,5-OAS induction during treatment were similar. AA patients showed a smaller decline in serum HCV RNA during the first 28 days of treatment (P < .001) and a lower EVR (65% vs 83%). AA and CA with EVR had significantly higher serum peginterferon conce...Continue Reading

References

Oct 6, 1998·Annual Review of Biochemistry·G R StarkR D Schreiber
Aug 29, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P GlueR P Clement
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Feb 26, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xuhuai JiXiao-Song He
Oct 16, 2003·Journal of the National Cancer Institute·Dawn HershmanAlfred I Neugut
May 28, 2004·The New England Journal of Medicine·Andrew J MuirUNKNOWN Atlantic Coast Hepatitis Treatment Group
Jun 9, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Lennox J JeffersK Rajender Reddy
Jan 5, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Heather J RibaudoUNKNOWN Adult AIDS Clinical Trials Group Study
Jul 28, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xiao-Song HeHarry B Greenberg

❮ Previous
Next ❯

Citations

Nov 28, 2012·Antimicrobial Agents and Chemotherapy·Mamta K JainTawanda Gumbo
Sep 3, 2014·The American Journal of Gastroenterology·Sammy SaabFritz Francois
Oct 16, 2012·Digestive Diseases and Sciences·Mauricio Lisker-Melman, José L Walewski
Nov 27, 2010·Journal of Viral Hepatitis·A J MuirJ McCone
Dec 17, 2008·Journal of Hepatology·Andrew W Tai, Raymond T Chung
Oct 9, 2019·Expert Opinion on Drug Metabolism & Toxicology·Ming-Lun YehWan-Long Chuang

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.